- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03213223
Retention of Women in the PMTCT (Prevention of Mother-to-child Transmission of HIV)
Retention-in-care of Women in the Elimination of Mother-to-child Transmission of HIV (eMTCT) Option B Plus Program in Mashonaland East, Zimbabwe: a Mixed Method Study
EXECUTIVE SUMMARY RESEARCH QUESTION TO BE ADDRESSED BY THIS PROPOSAL What are the factors associated with retention-in-care of women enrolled in the eMTCT Option B+ program at eMTCT (elimination of mother-to-child transmission of HIV) sites with high retention-in-care compared to eMTCT sites with low retention in care? Hypotheses Null hypothesis H0: The attributable rate of low retention-in-care of women in the eMTCT program at eMTCT sites equals zero.
Alternative hypothesis HA: The attributable risk of low retention-in-care of women in the eMTCT program at eMTCT sites is not equal to zero.
RATIONALE FOR RESEARCH There is poor retention of women along the PMTCT (prevention of mother to child transmission of HIV) cascade. Retention in eMTCT refers to documented regular participation of the pregnant woman, confirmed HIV positive, together with her child or children not yet confirmed as HIV-positive, in all prescribed activities aimed at preventing transmission of HIV from her to the child, and scheduled or unscheduled HIV-care related visits, measured during or at the end of care. It results in uninterrupted supply of ART (antiretroviral therapy). Retention in PMTCT ranges between 10.6% and 76.5% in other countries. In Zimbabwe it was found to drop from 83% at second pick up of antiretroviral drugs to 45% at fourth pick up of antiretroviral drugs. Poor retention in PMTCT leads to poor health outcomes in the mother and the baby. These include increased viral load, reduced CD4 count, reduced adherence to ART, emergency of drug resistant HIV strains, reduced quality of life, increased frequency of opportunistic infections, increased all-cause hospitalizations and death of women and children. HIV infection contributes to between 6 and 20% of maternal deaths. On the other hand, about 14% of all new infections are due to MTCT (mother to child transmission of HIV).
Retention in care is better at some clinics and hospitals. The purpose of the study will be to determine the factors associated with retention-in-care of women enrolled in the eMTCT Option B+ program at eMTCT sites.
The following objectives will be addressed in the study:
- To assess the PMTCT Option B Plus program at selected eMTCT sites.
- To determine the prevalence of retention among women enrolled in the eMTCT Option B+ program at selected eMTCT sites.
- To determine the incidence of attrition among women enrolled in the eMTCT Option B+ program at selected eMTCT sites.
- To identify factors associated with variability in levels of retention-in-care of women in the eMTCT Option B+ program at selected eMTCT sites.
- To explore the barriers and facilitators of retention among women enrolled in the eMTCT Option B+ program.
METHODS The study is being done through a nested, embedded, mixed methods study with priority given to a prospective cohort methodology. The supplementary design is a simple descriptive qualitative design carried out through focus group discussions. A mixed methods design caters for the weaknesses in either a qualitative or a quantitative design. Hence, it is ideal in study of complex human issues such as retention in the PMTCT Option B Plus program.
In the study, 462 pregnant women enrolled for PMTCT Option B Plus will be followed up for 12 months in an open cohort. The sample size was calculated using Stata software based on a power of 0.8, a margin of error of 0.05, a design effect of 1.1 and a retention rate of 0.45. Six randomly selected eMTCT sites in Mashonaland East Province were chosen for the study. Retention rate at the sites since 2013 will be calculated. Three sites with lower retention will be considered as the exposure sites. The other 3 sites will be the unexposed sites. Option B Plus, a recently introduced and recommended PMTCT option, was meant to benefit pregnant women, in addition to their children and sexual partners. Hence, the involvement of women as participants. Four focus group discussions will also be done, with nursing mothers to ascertain the barriers and facilitators of retention in PMTCT Option B plus. Included in the study will be HIV positive pregnant and nursing women coming for PMTCT Option B Plus. Women who can communicate in English or Shona and are without psychiatric conditions will also be included. Emancipated minors, below 18 years of age will also be included. Excluded from the study will be women enrolled in PMTCT Options A or B, women with psychiatric conditions or those who are too ill to participate. The study was approved by The Medical Research Council of Zimbabwe. Signed voluntary consent is sought from participants. Data is being collected through questionnaires and audio-taped focus group discussions. Follow-up data will also be extracted from eMTCT registers at respective eMTCT sites. Data is kept in locked cabinets only accessible to the principal investigator and the supervisors.
Study Overview
Status
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Mashonaland East
-
Marondera, Mashonaland East, Zimbabwe
- Mashonaland East Province (Mutoko Hospital, Murewa Hospital, Kunaka Hospital, Nharira Hospital, Chichu Clinic, Epworth Polyclinic)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- women 15-49 years. On PMTCT tes and treat strategy or Option B+
Exclusion Criteria:
- mentally unstable women or not enrolled at the study sites for PMTCT. Women enrolled in Option B Censoring - after a miscarriage, still birth, on leaving the PMTCT program and at the end of the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retention in care based on record review and follow up data
Time Frame: One follow-up per 3-month period, up to 12 months
|
Missed visit count (number of missed visits), Dichotomous missed visit (more than one missed visit), Visit adherence (number of kept visits divided by the total number of scheduled visits), Four month constancy (the number of four month intervals in which the individual came for PMTCT at least once), 6-month gap (no visit in a 6-month period), HRSA HAB (Health Resources and Services administration HIV-AIDS Bureau) [2 kept visits separated by at least 90 days in a year)
|
One follow-up per 3-month period, up to 12 months
|
Attrition from PMTCT (determined through survival analysis based on Cox proportional hazards regression)
Time Frame: One follow-up per 3-month period, up to 12 months
|
Death or loss to follow - up from PMTCT
|
One follow-up per 3-month period, up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Barriers and enablers of retention (focus group discussions)
Time Frame: One focus group per week, up to 4 weeks, (total of four focus group discussions)
|
Perceived barriers and facilitators of retention.
Focus group discussions analysed through latent content analysis)
|
One focus group per week, up to 4 weeks, (total of four focus group discussions)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Augustine Ndaimani, DPhil MD (Student), University of Zimbabwe
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- A2087
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prevention of Mother-to-child Transmission of HIV
-
French National Agency for Research on AIDS and...RecruitingMother to Child Transmission of HIVFrance
-
University of KwaZuluUniversity of California, San Francisco; Centers for Disease Control and Prevention and other collaboratorsCompletedEffectiveness of an HIV-adapted IMCI Training and Supervision Programme for Community Health WorkersInfant Feeding Practices | Prevention of Mother-to-child Transmission of HIV | Antenatal Health Care Utilization | Postnatal Health Care UtilizationSouth Africa
-
Harvard School of Public Health (HSPH)Elton John AIDS Foundation; Management and Development for Health, Tanzania; Comic...CompletedPregnancy | Mother-to-child Transmission of HIVTanzania
-
Elizabeth Glaser Pediatric AIDS FoundationUniversity of Rwanda; Ministry of Health, RwandaCompletedMother-to-child HIV TransmissionRwanda
-
ANRS, Emerging Infectious DiseasesNot yet recruitingMother to Child HIV Transmission
-
Chinese University of Hong KongRecruitingGut Microbiome | Mother to Child TransmissionChina
-
ANRS, Emerging Infectious DiseasesCompletedMother to Child HIV TransmissionGuinea
-
Pacific Institute for Research and EvaluationFogarty International Center of the National Institute of Health; Kenya Medical... and other collaboratorsActive, not recruitingHIV | Pregnancy in Adolescence | Social Stigma | Mother to Child Transmission | Self DisclosureKenya
-
ANRS, Emerging Infectious DiseasesRecruitingMother to Child Transmission of HIVFrance, French Guiana, Guadeloupe, Martinique
-
University Hospital, BordeauxCompletedTransmission of Information to the Relatives After Genetic DiagnosisFrance